The global pharmaceutical sterility testing market size was valued at USD 733.7 Million in 2016. It is estimated to register a CAGR of 11.8% over the forecast period. Government investments in the healthcare industry, increasing R&D activities and number of drug launches, and rising focus on quality and sterility are projected to drive the market. According to the UNESCO report, the U.S., China, Japan, and Germany were among the top five nations in terms of R&D expenditure in 2016.
The U.S. spends nearly 2.7% of its GDP on R&D, whereas China spends approximately 2.0% of GDP on R&D activities. Annual R&D expenditure of China has increased by nearly 70.9% from 2012, as per the CNBC report. Heavy R&D investments are anticipated to increase the number of product innovations; thereby, indirectly facilitating the sterility testing market.
Several developing nations streamlined their drug approval regulatory timelines to accelerate drug launch in order to meet rising healthcare demands. Such regulatory changes are projected to boost market growth. Moreover, drugs such as Elagolix and Lanadelumab are biopharmaceutical products requiring special sterility testing procedure, and thereby, launch of such products is said to bolster the growth of the market.
The FDA relaxed its regulatory guidelines allowing adoption of modern and sophisticated sterility testing techniques by contract labs and manufacturers. This initiative is estimated to provide flexibility to labs and manufacturers in adopting sterility procedures suitable for assuring safety of their innovative products.
On the basis of type, the market is segmented into in-house and outsourcing. The outsourcing segment led the market share accounting for USD 400.9 million in 2016 and is projected to grow at a rapid pace over the forecast period.
The in-house sterility testing market is an essential part of quality assurance and Goof Manufacturing Practices (GMP) for the manufacturers of pharmaceutical, biopharmaceuticals, and medical devices. Sterility testing is mandatory for release of each batch, which facilitates the segment’s growth.
Outsourcing of sterility testing is an attractive alternative. Some companies do not have the infrastructure to conduct quality sterility testing and therefore prefer to outsource these services. Moreover, outsourcing also saves time and cost by reducing the need of training personnel and purchase of sterility testing equipment. However, the quality of sterility testing services depends on the outsourced lab as an ill-equipped lab can deliver inaccurate test results. This facilitates the demand to outsource to high-quality sterility testing laboratories.
The key end-use segments include compounding pharmacies, medical devices and pharmaceutical companies, and others such as hospitals, biopharmaceuticals, clinics, and research labs. The others segment is projected to register a lucrative CAGR over the forecast period owing to increasing R&D activities, outsourcing services, and rise in innovative biopharmaceutical products.
The pharmaceutical companies segment held the largest share in the pharmaceutical sterility testing market in 2016. This can be attributed to regulatory requirement to conduct sterility testing for each batch release to ensure product safety. These companies adhere to GMP and ICH standards prior to drug approval and launch, thereby contributing to market growth.
The bacterial endotoxin testing segment accounted for the highest market share in 2016 and is anticipated to register a lucrative CAGR over the forecast period. This can be attributed to the ongoing technological advancements in this segment.
The sterility and bioburden testing segments are anticipated to witness rapid growth over the forecast period. Increasing emphasis on product quality, along with the rising number of drug and medical devices launches, is anticipated to contribute towards the expansion of these segments.
Bioburden and sterility testing along with sterilization process validation are crucial aspects of GMP for assuring the safety of the end products. Sterility and bioburden testing are conducted on medical devices or its components to determine the total viable microorganism count prior to the sterilization process, thereby facilitating the growth of these segments.
Based on sample, the global market is segmented into sterile dugs, medical devices, and biologics and therapeutics. The sterile drugs held the largest market share in 2016 due to the high adoption of several techniques adopted for product safety.
The biologic and therapeutics segment would witness a remunerative growth over the forecast period. This is attributed to the factors such as growing number of technological advancements in sterility testing procedures, biosimilars, vaccines, and other biologics along with regulatory mandates to ensure the sterility of biologics & therapeutics.
In terms of region, North America held the largest market share in 2016 and is anticipated to expand at CAGR of 11.7.over the forecast period. This can be attributed to the presence of a large number of international and domestic players in this region. Asia Pacific is anticipated to witness the fastest growth during the forecast period.
This can be attributed to increasing harmonization of the regulatory standards with the ICH standards in developing nations. Moreover, many emerging economies in the region are undertaking various initiatives to boost the domestic pharmaceutical market and are encouraging multinational companies to set up operations in the region. Such initiatives are likely to contribute towards the regional development.
The global market is characterized by the presence of a large number of global and domestic companies. The market is also fragmented due to the presence of contract service providers and research laboratories.
Some of the key companies in this market are SGS SA; Toxikon, Inc.; Pace Analytical Services, LLC; Boston Analytical; Charles River Laboratories International, Inc.; and Nelson Laboratories. Regional expansions and M&A activities are key strategies undertaken by most of these companies. For instance, in July 2015, Charles River Laboratories acquired Celsis International Ltd to strengthen the company’s microbiology testing capabilities.
Report Attribute |
Details |
Market size value in 2020 |
USD 1,017.5 million |
Revenue forecast in 2025 |
USD 1,998.6 million |
Growth Rate |
CAGR of 11.8% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Type, test type, end-use, sample, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; Japan; China; Brazil; Mexico; South Africa; Saudi Arabia |
Key companies profiled |
SGS SA; Toxikon, Inc.; Pace Analytical Services, LLC; Boston Analytical; Charles River Laboratories International, Inc.; Nelson Laboratories |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global pharmaceutical sterility testing market report on the basis of type, test type, end-use, sample, and region:
Type Outlook (Revenue, USD Million, 2014 - 2025)
In-house
Outsourcing
Test type Outlook (Revenue, USD Million, 2014 - 2025)
Sterility Testing
Bioburden Testing
Bacterial Endotoxin Testing
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Compounding Pharmacies
Medical Devices Companies
Pharmaceutical Companies
Others
Sample Outlook (Revenue, USD Million, 2014 - 2025)
Sterile Drugs
Medical Devices
Biologics & Therapeutics
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
The U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
Saudi Arabia
b. The global pharmaceutical sterility testing market size was estimated at USD 911.7 million in 2019 and is expected to reach USD 1,017.5 million in 2020.
b. The global pharmaceutical testing sterility market is expected to grow at a compound annual growth rate of 11.8% from 2019 to 2025 to reach USD 1,998.6 million by 2025.
b. North America dominated the Pharmaceutical sterility testing market with a share of 49.7% in 2019. This is attributed to the increasing number of pharmaceutical industries within the U.S. and Canada and an increasing presence of the number of major market players this region is expected to contribute significantly to the market growth.
b. Some key players operating in the Pharmaceutical testing sterility market include SGS SA; Toxikon, Inc.; Pace Analytical Services, LLC; Boston Analytical; Charles River Laboratories International Inc.; Nelson Laboratories and others.
b. Key factors that are driving the market growth include supportive government investments in healthcare industry, increasing R&D activities, increasing number of drug launches, and increasing focus on quality and sterility.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.